Dr. Reddy's Launches Novel Acid Blocker Tegoprazan in India Under Brand PCAB

Dr Reddy's Laboratories has introduced Tegoprazan, a next-generation potassium-competitive acid blocker (P-CAB), in India under the brand name PCAB®. The drug is designed to treat acid-related gastrointestinal diseases, including GERD and gastric ulcers. In clinical trials, 99% of GERD patients achieved endoscopic healing by Week 8. Tegoprazan is already approved in 21 countries and aims to address the needs of approximately 38% of the Indian population affected by acid peptic diseases. This launch is part of Dr Reddy's exclusive partnership with South Korea's HK inno.N Corporation.